Immutep Ltd
ASX:IMM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sambhaav Media Ltd
NSE:SAMBHAAV
|
IN |
|
N
|
Nanoform Finland Oyj
OMXH:NANOFH
|
FI |
Immutep Ltd
Cash
Immutep Ltd
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immutep Ltd
ASX:IMM
|
Cash
AU$43.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash
$129.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
31%
|
|
|
CSL Ltd
ASX:CSL
|
Cash
$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash
AU$20.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash
AU$141.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
Glance View
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
See Also
What is Immutep Ltd's Cash?
Cash
43.1m
AUD
Based on the financial report for Dec 31, 2025, Immutep Ltd's Cash amounts to 43.1m AUD.
What is Immutep Ltd's Cash growth rate?
Cash CAGR 5Y
6%
Over the last year, the Cash growth was 36%. The average annual Cash growth rates for Immutep Ltd have been -14% over the past three years , 6% over the past five years .
